In recent years, multigene tests such as Oncotype DX, MammaPrint, Breast Cancer Index, Prosigna (PAM50), and EndoPredict have transformed the management of hormone-receptor positive (HR+)/human epidermal growth factor-receptor 2 negative (HER2–) early breast cancer (BC). The gene discussed is HR; the disease is breast cancer.